cefpiramide and Fetal-Membranes--Premature-Rupture

In vivo transfer and therapeutic efficiency of a new cephalosporin derivative, cefpiramide (CPM) have studied in perinatal and gynecologic field. The following results have been obtained. The level of CPM transferred to uterus and adnexa was higher than its MIC against majority of Gram-negative bacilli, such as E. coli. This drug as demonstrated its efficiency, in treating 3 infection cases refractory to cephalothin, ampicillin and cephalexin, out of which 1 had "excellent" and 2 had "good" results. No side effect was evidenced in any of our patients. In conclusion, this drug has satisfactory tissue transfer as well as sufficient safety and excellent efficiency in treatment of perinatal infection cases.

Topics: Adnexa Uteri; Adult; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Fetal Membranes, Premature Rupture; Genital Diseases, Female; Humans; Hysterectomy; Kinetics; Pregnancy; Uterus

Clinical study on cefpiramide (CPM, SM-1652), a new cephalosporin antibiotic, was carried out and the following results were obtained. CPM was intravenously administrated at a daily dose of 2 g to 8 cases including 2 cases with intrauterine infection, 3 cases with adnexitis, 2 cases with intrapelvic infection and 1 case with external genital infection. All cases responded to the drug, and marked response was seen in 2 cases, moderate response in 6 cases. Neither side effects nor abnormal values in clinical laboratory findings attributable to the drug were seen.

Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Fetal Membranes, Premature Rupture; Genital Diseases, Female; Humans; Hysterectomy; Middle Aged; Pregnancy